Beginning March 4, 2022, we will no longer mail appeal decision letters for Medicare Advantage and commercial plans. Instead, you’ll be able to view them digitally 24/7 starting on the day they’re generated. You’ll receive an email notice when new letters are available.
These changes affect most* Medicare Advantage (including Dual Special Needs) and commercial network medical health care professionals (primary and ancillary) and facilities nationwide.
We encourage you to share this information and start using our digital solutions ahead of each change. If you work with an outside vendor, such as a revenue cycle management company, for your mail processing, please talk with them to see how the change may affect current workflows. Those receiving paper appeal decision letters today will also receive a reminder insertedin their mailings prior to this change.
We’ll transition most* contracted health care professionals (primary and ancillary) and facilities from paper to digital communication in 2022. Look for announcements in UHCprovider.com/news90 days before mailings end so you have time to prepare. As new letters move to digital-only delivery, you can find them in Document Library.
Required email contact information
Health care professionals and facilities in the UnitedHealthcare network are required to do business with us electronically. We must have a valid email address on file to send you required notifications and important information.
Please contact UnitedHealthcare Provider Services, toll-free, at 877-842-3210, TTY/RTT 711,
7 a.m.–5 p.m. CT, Monday–Friday.
*Currently excludes: UnitedHealthcare Commercial and Medicare Plans of Colorado; Behavioral Health; Medicare supplement products; Sierra Health and Life; Rocky Mountain Health Plan; UnitedHealthcare West; UnitedHealthOne; UMR; UnitedHealthcare Global; Student Resources; Optum VA Community Care Network (CCN); Highly Integrated Dual Eligible Special Needs Plans (HIDE SNP); Fully Integrated Dual Eligible Special Needs Plans (FIDE SNP); Medicare-Medicaid Plans (MMP); Part D Pharmacy Appeals.